AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23440253 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly volunteering with elementary school‐aged children for 2 months
Number of subjects: 106
Study 23440253 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 106
Study 22356030 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine group
Number of subjects: 120
Study 22356030 — intervention group
Group type: EXPERIMENTAL
Intervention: TTH group
Number of subjects: 120
Study 22356030 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 19524329 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic physical activity, recreational activities, nutritional and food manipulation training visits, with a medical student assigned for periodical contact.
Number of subjects: 700
Study 19524329 — intervention group
Group type: COMPARATOR
Intervention: Normal activities during observational period.
Number of subjects: 700
Study 16574041 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 1295
Study 16574041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1295
Study 10525745 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple the maintenance dose every 72 h
Number of subjects: 16
Study 10525745 — intervention group
Group type: COMPARATOR
Intervention: Double the maintenance dose every 48 h
Number of subjects: 16
Study 10525745 — intervention group
Group type: COMPARATOR
Intervention: Maintenance dose every 24 h
Number of subjects: 16
Study 8546911 — intervention group
Group type: EXPERIMENTAL
Intervention: ICR62 2.5 mg
Number of subjects: 20
Study 8546911 — intervention group
Group type: EXPERIMENTAL
Intervention: ICR62 10 mg
Number of subjects: 20
Study 8546911 — intervention group
Group type: EXPERIMENTAL
Intervention: ICR62 20 mg
Number of subjects: 20
Study 8546911 — intervention group
Group type: EXPERIMENTAL
Intervention: ICR62 40 mg
Number of subjects: 20
Study 8546911 — intervention group
Group type: EXPERIMENTAL
Intervention: ICR62 100 mg
Number of subjects: 20
Study 1884746 — intervention group
Group type: EXPERIMENTAL
Intervention: HR (2 tablets of 500 mg/day)
Number of subjects: 16
Study 1884746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6346476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisobitan
Number of subjects: 140
Study 6346476 — intervention group
Group type: COMPARATOR
Intervention: Estradurin/Etivex (estrogen preparation)
Number of subjects: 140
Study 6346476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisobitan (poorly differentiated cancer)
Number of subjects: 140
Study 6346476 — intervention group
Group type: COMPARATOR
Intervention: Estracyt (poorly differentiated cancer)
Number of subjects: 140
Study 31525174 — intervention group
Group type: EXPERIMENTAL
Intervention: Triaxial accelerometry (ActiGraph GT3X+) measuring physical activity intensity across three axes
Number of subjects: 841
Study 31525174 — intervention group
Group type: COMPARATOR
Intervention: Overall PA (counts per minute) from the vertical axis only
Number of subjects: 841
Study 29370756 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based (CB) exercise
Number of subjects: 0
Study 29370756 — intervention group
Group type: COMPARATOR
Intervention: Home-based (HB) exercise
Number of subjects: 0
Study 27327283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 46
Study 27327283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 1.0 mg
Number of subjects: 46
Study 27327283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg and 1.0 mg
Number of subjects: 46
Study 24445223 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician telepresence (PTP)
Number of subjects: 0
Study 24445223 — intervention group
Group type: COMPARATOR
Intervention: Traditional nurse triage (TNT)
Number of subjects: 0
Study 22045039 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 874
Study 22045039 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 874
Study 22045039 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 874
Study 22045039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study 22045039 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (150 and 300 mg/day)
Number of subjects: 874
Study 22045039 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day and Escitalopram
Number of subjects: 874
Study 21146654 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard activated clotting time (ACT)-guided doses of intravenous UFH
Number of subjects: 4000
Study 21146654 — intervention group
Group type: COMPARATOR
Intervention: Non-ACT-guided weight-adjusted low dose of intravenous UFH
Number of subjects: 4000
Study 21146654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (Standard and Low-dose)
Number of subjects: 4000
Study 17986897 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 60
Study 17986897 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 60
Study 17986897 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 60
Study 17986897 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study 16282047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 16282047 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments for OA
Number of subjects: 0
Study 11980684 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 1008
Study 11980684 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 1008
Study 9499327 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/d
Number of subjects: 96
Study 9499327 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 300 mg/d
Number of subjects: 96
Study 9499327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9499327 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/d and 300 mg/d
Number of subjects: 96
Study 8907436 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants (one month and three months of age)
Number of subjects: 0
Study 8907436 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants (one month and three months of age)
Number of subjects: 0
Study 8907436 — intervention group
Group type: COMPARATOR
Intervention: Control serum from healthy adults (22 to 30 years of age)
Number of subjects: 0
Study 31563366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cupping on calf muscle myofascial trigger points (MTrPs)
Number of subjects: 71
Study 31563366 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises and ankle dorsiflexion exercises
Number of subjects: 71
Study 31563366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 71
Study 29190605 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of colistin
Number of subjects: 40
Study 29190605 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of colistin
Number of subjects: 40
Study 25622198 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent smoking cessation (CSC) intervention
Number of subjects: 151
Study 25622198 — intervention group
Group type: COMPARATOR
Intervention: Delayed smoking cessation (DSC) intervention
Number of subjects: 151
Study 25622198 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily assessments during CSC
Number of subjects: 151
Study 23398585 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective suppression condition
Number of subjects: 127
Study 23398585 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mindset condition
Number of subjects: 127
Study 23398585 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 127
Study 21496653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 86
Study 21496653 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 86
Study 21246795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract capsules (equiv. 17,000 mg of fresh fruit) taken twice a day, 4 days before and 5 days after surgery
Number of subjects: 286
Study 21246795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cranberry extract)
Number of subjects: 286
Study 17473001 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 22
Study 17473001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15058118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared morphine solution 10 mg (Group Ten)
Number of subjects: 105
Study 15058118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared morphine solution 5 mg (Group Five)
Number of subjects: 105
Study 15058118 — intervention group
Group type: COMPARATOR
Intervention: No syringe (Group Zero)
Number of subjects: 105
Study 15058118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared morphine solution (Group Ten and Group Five)
Number of subjects: 105
Study 11464349 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine (0.166%, 2 to 8 mL/h) and diamorphine (0.2 to 0.8 mg/h) for 24 hours before and during operation (14 patients)
Number of subjects: 30
Study 11464349 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative perineural catheter infusing bupivacaine (0.25%, 10 mL/h) (16 patients)
Number of subjects: 30
Study 11464349 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural group
Number of subjects: 30
Study 11464349 — intervention group
Group type: COMPARATOR
Intervention: Perineural group
Number of subjects: 30
Study 9483593 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive teaching book
Number of subjects: 143
Study 9483593 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative teaching (Control)
Number of subjects: 143
Study 7993161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (verbal instructions and handout about medication)
Number of subjects: 0
Study 7993161 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual discharge instructions)
Number of subjects: 0
Study 2910050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin, 0.2 mg/kg per dose, three doses on the fourth day of life
Number of subjects: 38
Study 2910050 — intervention group
Group type: COMPARATOR
Intervention: No indomethacin (control group)
Number of subjects: 38
Study 2910050 — intervention group
Group type: COMPARATOR
Intervention: Infants without evidence of a PDA (third group)
Number of subjects: 38
Study 790351 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride 32 mg daily for 16 weeks
Number of subjects: 28
Study 790351 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 28
Study 28616796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral topical anesthetic eye drops (Group 2)
Number of subjects: 180
Study 28616796 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral topical anesthetic eye drops (Group 1)
Number of subjects: 180
Study 28610898 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of levonorgestrel contraceptive implants (75 mg, 2-rod system) within 5 days of delivery
Number of subjects: 205
Study 28610898 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of levonorgestrel contraceptive implants (75 mg, 2-rod system) at 6 weeks postpartum
Number of subjects: 205
Study 28610898 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of levonorgestrel contraceptive implants
Number of subjects: 205
Study 28610898 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of levonorgestrel contraceptive implants
Number of subjects: 205
Study 25434574 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (15% energy restricted diet for 4 weeks)
Number of subjects: 50
Study 21679246 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 250, 500, 1000, 1250 or 1500 mg of mildronate capsules
Number of subjects: 40
Study 21679246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of 500 mg of mildronate capsules three times a day for 13 days
Number of subjects: 40
Study 21679246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerability assessment throughout the study
Number of subjects: 40
Study 21695630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianxianning
Number of subjects: 206
Study 21695630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 19728630 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronectomy
Number of subjects: 0
Study 19728630 — intervention group
Group type: COMPARATOR
Intervention: Total excision (control)
Number of subjects: 0
Study 17172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole treatment
Number of subjects: 301
Study 17172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative levodopa dose
Number of subjects: 301
Study 17172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative levodopa equivalent dose (levodopa plus pramipexole)
Number of subjects: 301
Study 17172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at onset of 65 years or older
Number of subjects: 301
Study 17172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoehn and Yahr stage of 2 or higher
Number of subjects: 301
Study 17172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of motor fluctuations
Number of subjects: 301
Study 17172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative levodopa equivalent dose
Number of subjects: 301
Study 17172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor fluctuations and dyskinesias
Number of subjects: 301
Study 14743580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-enriched lipid emulsion (4 g/l free cholesterol)
Number of subjects: 10
Study 14743580 — intervention group
Group type: COMPARATOR
Intervention: Conventional lipid emulsion (20% triglycerides)
Number of subjects: 10
Study 11070454 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg) dry-powder inhalation
Number of subjects: 14
Study 11070454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8878166 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (C, E, beta carotene)
Number of subjects: 0
Study 8878166 — intervention group
Group type: COMPARATOR
Intervention: Observational epidemiology
Number of subjects: 0
Study 1349492 — intervention group
Group type: EXPERIMENTAL
Intervention: abanoquil 0.25 mg
Number of subjects: 10
Study 1349492 — intervention group
Group type: EXPERIMENTAL
Intervention: abanoquil 0.5 mg
Number of subjects: 10
Study 1349492 — intervention group
Group type: EXPERIMENTAL
Intervention: abanoquil 1 mg
Number of subjects: 10
Study 1349492 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 3899971 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine vaginal douche
Number of subjects: 200
Study 3899971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 30956216 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone prophylaxis (150 mg IV bolus, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours)
Number of subjects: 46
Study 30956216 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 46
Study 30956216 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone prophylaxis
Number of subjects: 46
Study 30015649 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based interventions addressing traditional cardiovascular risk factors; details on dosage and duration not available.
Number of subjects: 0
Study 30015649 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based interventions, such as the Healing Hearts Together program; details on dosage and duration not available.
Number of subjects: 0
Study 30015649 — intervention group
Group type: COMPARATOR
Intervention: Couple-based interventions; details on dosage and duration not available.
Number of subjects: 0
Study 26437831 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestion-resistant maltodextrin (RMD)
Number of subjects: 66
Study 25135729 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture stimulation (EAS) at PC4 and PC6
Number of subjects: 60
Study 25135729 — intervention group
Group type: EXPERIMENTAL
Intervention: EAS
Number of subjects: 60
Study 25135729 — intervention group
Group type: COMPARATOR
Intervention: Control (general anesthesia only)
Number of subjects: 60
Study 25135729 — intervention group
Group type: COMPARATOR
Intervention: Sham (EA needles at PC4 and PC6 but no stimulation)
Number of subjects: 60
Study 25135729 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 25135729 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study 22574587 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (AD) 10 mg, once daily, combined with Baihua Xianglian Detoxification Recipe (BXDR) twice daily
Number of subjects: 240
Study 22574587 — intervention group
Group type: COMPARATOR
Intervention: Baihua Xianglian Detoxification Recipe (BXDR) combined with Adefovir dipivoxil (AD)
Number of subjects: 240
Study 21240151 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 400 mg/day
Number of subjects: 565
Study 21240151 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 600 mg/day
Number of subjects: 565
Study 21240151 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 800 mg/day
Number of subjects: 565
Study 21240151 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine IR 800 mg/day
Number of subjects: 565
Study 21240151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study 17912637 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for up to 5 years
Number of subjects: 4000
Study 17912637 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily for up to 5 years
Number of subjects: 4000
Study 15590845 — intervention group
Group type: EXPERIMENTAL
Intervention: Kapandji method (modified by Fritz et al.)
Number of subjects: 100
Study 15590845 — intervention group
Group type: COMPARATOR
Intervention: Conventional Kirschner wire fixation (Willenegger technique)
Number of subjects: 100
Study 15590845 — intervention group
Group type: EXPERIMENTAL
Intervention: Kapandji method
Number of subjects: 100
Study 12600115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous reduced glutathione (GSH) at a dose of 1200 mg twice a week for 12 weeks
Number of subjects: 42
Study 12600115 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO) at a dose of 3000U twice a week for 12 weeks
Number of subjects: 42
Study 9700247 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus tetracycline fibers
Number of subjects: 30
Study 9700247 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing only
Number of subjects: 30
Study 7981015 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine (10 mg three times daily)
Number of subjects: 16
Study 7981015 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (10 mg three times daily)
Number of subjects: 16
Study 2597598 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderex (bendrofluazide 5 mg and Inderal LA 160 mg)
Number of subjects: 21
Study 2597598 — intervention group
Group type: COMPARATOR
Intervention: Inderal LA (160 mg)
Number of subjects: 21
Study 2597598 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide (5 mg)
Number of subjects: 21
Study 4881072 — intervention group
Group type: EXPERIMENTAL
Intervention: Leningrad-16
Number of subjects: 100
Study 4881072 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz
Number of subjects: 100
Study 4881072 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 100
Study 30796762 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Moringa oleifera leaves meal (MLM)
Number of subjects: 315
Study 30796762 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Olea europaea leaves meal (OLM)
Number of subjects: 315
Study 30796762 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytogenic plant diets (various treatments)
Number of subjects: 315
Study 30796762 — intervention group
Group type: COMPARATOR
Intervention: Commercial diet (control)
Number of subjects: 315
Study 29805491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroid treatment (methylprednisolone)
Number of subjects: 120
Study 29805491 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid treatment (budesonide)
Number of subjects: 120
Study 29805491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroid treatment)
Number of subjects: 120
Study 27139820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib tablet formulation (140 mg)
Number of subjects: 98
Study 27139820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib tablet strengths (20, 40, and 60 mg)
Number of subjects: 98
Study 24673043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupuncture group (group C)
Number of subjects: 96
Study 24673043 — intervention group
Group type: COMPARATOR
Intervention: Restore interaction between the heart and the kidney group (group A)
Number of subjects: 96
Study 24673043 — intervention group
Group type: COMPARATOR
Intervention: Acupuncturing qiao mai group (group B)
Number of subjects: 96
Study 21870127 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with LLLT (TLG)
Number of subjects: 45
Study 21870127 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG)
Number of subjects: 45
Study 21870127 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with LLLT group (TLG)
Number of subjects: 45
Study 21870127 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study 20238203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic prosthetic mesh placed in a sublay position at the index operation
Number of subjects: 0